Showing results (1471-1480 of 2,287) with videos related to

Sort By:
Pageof 229
HIV Medicine|February 10, 2009
Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infectionV Valcour, T-M Yeh, R Bartt, et al.
HIV Medicine|February 10, 2009
Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136)P Yeni, A Lamarca, D Berger, et al.
HIV Medicine|February 12, 2009
Cost-effectiveness of HIV nonoccupational post-exposure prophylaxis in AustraliaD Guinot, M T Ho, I M Poynten, et al.
HIV Medicine|February 12, 2009
Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteersT N Kakuda, M Schöller-Gyüre, G De Smedt, et al.
HIV Medicine|February 13, 2009
Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteersF Tomaka, E Lefebvre, V Sekar, et al.
HIV Medicine|November 7, 2022
Prevalence of neuropsychiatric adverse events and associated factors among adult patients on dolutegravir attending Mulago ISS clinicJoyce Mwebaza, David Meya, Victor Musiime, et al.
HIV Medicine|September 20, 2022
Comparison between the impact of tenofovir alafenamide and that of abacavir on rapid kidney function decline: A retrospective observational studyShinichi Hikasa, Shota Shimabukuro, Kyoko Hideta, et al.
HIV Medicine|September 2, 2022
Immune restoration affects 10-year survival in people living with HIV/AIDSBogusz Jan Aksak-Wąs, Justyna D Kowalska, Piotr Ząbek, et al.
HIV Medicine|September 8, 2022
Iron status among HIV-infected adults during the first year of antiretroviral therapy in TanzaniaAjibola Ibraheem Abioye, Christopher R Sudfeld, Michael D Hughes, et al.
HIV Medicine|December 1, 2023
HIV pre-exposure prophylaxis services, provision, and delivery in the European treatment network of HIV, hepatitis and global emerging infectious diseases (NEAT ID)Geoffroy Liegeon, Annie Duffy, Caroline Brooks, et al.
Pageof 229